

Contents

1	The Perfect Storm	1
2	The Miracle	9
3	Resistance	15
	The Basics	15
	Antibiotics for Animals and Crops Lead to Resistance for People	16
	In Our Hospitals, Things Are Getting Critical	20
	Antibiotic Resistance Plus Toxin Production Equals Death	23
	Our Communities are Not Spared	25
	Resistance – Summing Up	27
4	The FDA	29
	We Need Them, but They Have Become Part of the Problem	29
	The FDA Increases Clinical Trial Design Stringency and Costs. Companies Abandon Antibiotic Research	32
	“Mild” Infections Require Placebo-Controlled Trials – Industry Balks	35
	New Antibiotics for Mild Infections Are Forced from the Market While Generic Antibiotics Are Still Approved in the Absence of Placebo-Controlled Trials	38
	The Ketek Scandal	38
	Pneumonia – The New Frontier. New Trial Requirements for Pneumonia Will Make Approval Much More Difficult and Costly and Sometimes Simply Infeasible	41
	The FDA Can Change Its Requirements After Completion of a Trial and then Require New Trials for Approval	44
	The FDA is Regulating Itself Out of the Antibiotics Business	46
	We Need Balance and Perspective from the FDA	47
	The FDA Makes It Difficult for Them to Obtain Good Advice	48
5	Europe	51
6	The Industry	57
	Antibiotics Form a Cornerstone of the Pharmaceutical Industry	57
	Resistance Should Create Opportunities	60

Industry Consolidation Reduces the Effort in Antibiotics	61
Antibiotics Are Not Financially Attractive in the Consolidated Industry	63
Industry Takes a Risk-Averse Approach to Its Clinical Trials, but Deprives Us of the Most Important Information	65
Discovery of New Antibiotics Is Becoming Harder	66
The US Market Share is Stagnant or Shrinking. Will the Industry be Able to Prioritize Ex-US Territories?	67
Research and Development Costs Increase, but Approvals Are Down	68
Some Good News for Everyone	69
Antibiotic R&D in Biotech Is Stymied by Late Stage Clinical Trial Costs	71
Biotech Is Still a High-Risk Proposition	73
7 Modest Proposals	77
The Role of Government	77
Government Loves a Task Force	77
Government Can Play Several Important Roles	79
The Transatlantic Taskforce on Antimicrobial Resistance	81
Government-Sponsored Research and Research Tools Are Required	81
Industry Incentives Will Probably Also Be Required. Europe Is Leading the Way in Thinking Here	82
The FDA (and EMEA)	84
The FDA and EMEA Both Must Adapt a More Balanced Approach to Antibiotics. Required Trial Designs Must Be Feasible	84
Do We Want New Antibiotics for Mild Infections? Is Bacterial Bronchitis in the Setting of Chronic Lung Disease a Mild Infection?	84
The FDA Must Modify Its Guidelines for Clinical Trials in Community Acquired Bacterial Pneumonia	85
The FDA Has to Stop Moving the Goal Posts in Mid-Stream	87
The FDA Has to Level the Playing Field with Generic Antibiotics	88
Congress Needs to Step Back from the FDA Especially Where Science Is Concerned	88
Our Government Needs Access to the Best Advice it Can Get	89
How About a Totally New Approach to Drug Development?	89
Communication Between the Industry and Physicians Is Required, but is Becoming More and More Restricted	91
What Should the Industry Be Doing?	92
The Current Large PhRMA Model Is not Viable. These Giants Need to Divide Themselves into Bite-Size Portions to Survive	93
8 Conclusions	97
Bibliography	101
Index	105